Journal article · 2023 · Open access
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
American Heart Journal, 267, 1–11 · Published 25 September 2023 · DOI 10.1016/j.ahj.2023.09.007
In brief
“Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics” is a 2023 journal article by Stephen James Nicholls and 19 co-authors, published in American Heart Journal. OpenAlex counts 293 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at American Heart Journal.
- Citations
- 293
- Most cited in
- 2025 (120)
- Field-weighted impact
- 42.82
- References
- 51
- Authors
- 20
Abstract
Tirzepatide, a once weekly GIP/GLP-1 receptor agonist, reduces blood glucose and body weight in people with type 2 diabetes. The cardiovascular (CV) safety and efficacy of tirzepatide have not been definitively assessed in a cardiovascular outcomes trial. Tirzepatide is being studied in a randomized, double-blind, active-controlled CV outcomes trial. People with type 2 diabetes aged ≥40 years, with established atherosclerotic CV disease, HbA1c ≥7% to ≤10.5%, and body mass index ≥25 kg/m2 were randomized 1:1 to once weekly subcutaneous injection of either tirzepatide up to 15 mg or dulaglutide 1.5 mg. The primary outcome is time to first occurrence of any major adverse cardiovascular event (MACE), defined as CV death, myocardial infarction, or stroke. The trial is event-driven and planned to continue until ≥1,615 participants experience an adjudication-confirmed component of MACE. The primary analysis is non-inferiority for time to first MACE of tirzepatide versus dulaglutide by demonstrating an upper confidence limit <1.05, which will also confirm superiority versus a putative placebo, and also to determine whether tirzepatide produces a greater CV benefit than dulaglutide (superiority analysis). Over 2 years, 13,299 people at 640 sites in 30 countries across all world regions were randomized. The mean age of randomized participants at baseline was 64.1 years, diabetes duration 14.7 years, HbA1c 8.4%, and BMI 32.6 kg/m2. Overall, 65.0% had coronary disease, of whom 47.3% reported prior myocardial infarction and 57.4% had prior coronary revascularization. 19.1% of participants had prior stroke and 25.3% had peripheral artery disease. The trial is fully recruited and ongoing. SURPASS-CVOT will provide definitive evidence as to the CV safety and efficacy of tirzepatide as compared with dulaglutide, a GLP-1 receptor agonist with established CV benefit.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Nicholls, S. J., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N. A., Zinman, B., Zoungas, S., Basile, J., Bartee, A. K., Miller, D. L., Nishiyama, H., Pavo, I. J., Weerakkody, G. J., Wiese, R. J., & D’Alessio, D. A. (2023). Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics. American Heart Journal, 267, 1–11. https://doi.org/10.1016/j.ahj.2023.09.007
MLA 9
Nicholls, Stephen James, et al. “Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics.” American Heart Journal, vol. 267, 2023, pp. 1–11. https://doi.org/10.1016/j.ahj.2023.09.007.
Chicago
Nicholls, Stephen James, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, Abraham Michael Lincoff, Darren K. McGuire, et al. 2023. “Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics.” American Heart Journal 267: 1–11. https://doi.org/10.1016/j.ahj.2023.09.007.
Harvard
Nicholls, S. J. et al. (2023) ‘Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics’, American Heart Journal, 267, pp. 1–11. doi:10.1016/j.ahj.2023.09.007.
IEEE
S. J. Nicholls et al., “Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics,” American Heart Journal, vol. 267, pp. 1–11, 2023, doi: 10.1016/j.ahj.2023.09.007.
BibTeX
@article{nicholls2023comparison,
title = {{Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics}},
author = {Nicholls, Stephen James and Bhatt, Deepak L. and Buse, John B. and Del Prato, Stefano and Kahn, Steven E. and Lincoff, Abraham Michael and McGuire, Darren K. and Nauck, Michael Albrecht and Nissen, Steven E. and Sattar, Naveed A. and Zinman, Bernard and Zoungas, Sophia and Basile, Jan and Bartee, Amy K. and Miller, Debra Lee and Nishiyama, Hiroshi and Pavo, Imre J. and Weerakkody, Govinda J. and Wiese, Russell J. and D’Alessio, David A.},
journal = {American Heart Journal},
year = {2023},
volume = {267},
pages = {1--11},
doi = {10.1016/j.ahj.2023.09.007},
url = {https://doi.org/10.1016/j.ahj.2023.09.007}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2021 | 1 | |
| 2023 | 5 | |
| 2024 | 72 | |
| 2025 | 120 | |
| 2026 | 95 |
Its field-weighted citation impact is 42.82: it has been cited 42.82 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- tirzepatide
- dulaglutide
- type 2 diabetes
- atherosclerotic cardiovascular disease
- major adverse cardiovascular events
- GIP/GLP-1 receptor agonist
- cardiovascular safety
- non-inferiority
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Nicholls, S. J., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N. A., Zinman, B., Zoungas, S., Basile, J., Bartee, A. K., Miller, D. L., Nishiyama, H., Pavo, I. J., Weerakkody, G. J., Wiese, R. J., & D’Alessio, D. A. (2023). Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics. American Heart Journal, 267, 1–11. https://doi.org/10.1016/j.ahj.2023.09.007
How many times has this paper been cited?
293 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at American Heart Journal: sign in and open the full text from this page.
Who wrote this paper?
Stephen James Nicholls, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, Abraham Michael Lincoff, Darren K. McGuire, Michael Albrecht Nauck, Steven E. Nissen, Naveed A. Sattar, Bernard Zinman, Sophia Zoungas and 8 more.
What is the DOI of this paper?
10.1016/j.ahj.2023.09.007, permanently at https://doi.org/10.1016/j.ahj.2023.09.007. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.